• Home
  • GROUP HOME
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • R&D
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Firalis
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • R&D
  • Quality
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
contact

Article on "Amoneta Diagnostics"

You can have a part of Amoneta Diagnostics via Crowdfunding operation open now !

Click here to know more.

 

 

 

 

 

 

 

 

 

 

Amoneta develops a biomarker based non-invasive, simple and realiable blood test for early diagnosis of Alzheimer supported by several EU funding.

As agreed by the majority of KOLs; "an efficient and simple diagnosis of Alzheimer's Disease based on innovative biomarkers is essential to come up with better treatments".

22.11.2018

Follow us on LinkedIn